We’re beating heart disease

The Food and Drug Administration recently granted approval for a new oral medication called enlicitide. This daily pill offers a significant advancement in cardiovascular health by reducing dangerous LDL cholesterol levels by nearly 60 percent. For patients who previously relied on injectable treatments or complex prescriptions, this tablet provides a more accessible path to managing heart health.

Heart disease remains the primary cause of death in the United States. In 2025 alone, the condition resulted in over 694,000 fatalities, surpassing the death toll of all cancer types combined. The approval of enlicitide marks a shift in how medical professionals approach the prevention of cardiovascular complications on a mass scale.

While medical breakthroughs often focus on high-tech interventions like gene editing, this pill represents a practical improvement in patient care. By simplifying the management of cholesterol, the medical community aims to lower the high mortality rates associated with heart disease. This development highlights the steady progress being made in managing chronic health conditions through accessible pharmacology.